JHJonathan Holbrook

Jonathan Holbrook

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonathan Holbrook has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and potential human and economic impact of a broadly protective betacoronavirus vaccine

    by George William Carnell, Robert Vendramelli, Charles W Whittaker, Jonathan A. Holbrook, Srivatsan Parthasarathy, Hazel Stewart, Joey Olivier, Bryce Warner, Thang Truong, Charlotte George, et al.

    Within two decades, three different betacoronaviruses (β-CoV) have spilled over from animals to humans causing high consequence diseases, the most recent causing the COVID-19 pandemic. Using computational antigen design technology, we developed a single multivalent vaccine candidate capable of broadly neutralising diverse animal and human β-CoVs. We then demonstrated that this single vaccine could protect mice from lethal infection against the three genetically distinct human SARS-CoV, MERS-CoV and SARS-CoV-2 viruses. Epidemiological modelling revealed that a single broadly protective β-CoV vaccine (BPBV) of moderate efficacy (50% against severe disease) could have averted a significant fraction of deaths during the SARS-CoV-2 pandemic, depending on the degree of clinical preparedness established pre-pandemic. Deaths averted by the BPBV varied in our simulations, ranging from 47% if the BPBV had been clinically evaluated through to a phase 2 trail, and ready for vaccine efficacy trials early during an initial outbreak, to 13% if phase 1 clinical testing of such a BPBV had not yet been initiated. Taken together we provide pre-clinical evidence of robust efficacy of a single BPBV vaccine candidate and modelling data demonstrating the significant positive impact on human health and significant economic benefit to national economies which would be achieved by clinically advancing and stockpiling a Phase 3 ready BPBV vaccine in the event of new virus outbreaks.

  • Open Access

    Covering All Bases: A Computational Method to Design Broad-spectrum T-cell-inducing Vaccines Applied to Betacoronaviruses

    by Phil Palmer, Sofiya Fedosyuk, Srivatsan Parthasarathy, Jonathan Holbrook, Charlotte George, Laura O’reilly, Lara Wiegand, George William Carnell, Jonathan Luke Heeney, Sneha Vishwanath

    Antigenically diverse pathogens, such as coronaviruses, pose substantial threats to global health. This highlights the need for effective broad-spectrum vaccines that elicit robust immune responses in a large proportion of the human population against a wide array of pathogen variants. Here, we introduce Spectravax, an AI-enabled computational method to design broad-spectrum vaccines that account for genetic diversity in both the host and pathogen populations. Using Spectravax, we designed a nucleocapsid (N) antigen to elicit cross-reactive immune responses to viruses from the Sarbecovirus and Merbecovirus subgenera of Betacoronaviruses . In silico analyses demonstrated superior predicted host and pathogen coverage for Spectravax compared to wild-type sequences and existing computational designs. Experimental validation in mice supported these predictions: Spectravax N elicited robust immune responses to SARS-CoV, SARS-CoV-2, and MERS-CoV—the three coronaviruses responsible for major outbreaks in humans since 2002—while wild-type and existing computational designs elicited limited responses. Furthermore, we were able to identify the MERS-CoV N epitopes responsible for Spectravax’s cross-reactivity. Thus, we advance the rational design of broad-spectrum vaccines for pandemic preparedness.

  • Open Access

    Natural killer cells have an activated profile in early Parkinson's disease

    by J. Holbrook, B. Patel, M. Camacho, L. Kahanawita, J. Greenland, C.H. Williams-Gray


  • Open Access

    Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations

    by Samuel Lara-Reyna, Jonathan Holbrook, Heledd H. Jarosz-Griffiths, Daniel Peckham, Michael F. McDermott

    Cystic fibrosis (CF) is one of the most common life-limiting recessive genetic disorders in Caucasians, caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). CF is a multi-organ disease that involves the lungs, pancreas, sweat glands, digestive and reproductive systems and several other tissues. This debilitating condition is associated with recurrent lower respiratory tract bacterial and viral infections, as well as inflammatory complications that may eventually lead to pulmonary failure. Immune cells play a crucial role in protecting the organs against opportunistic infections and also in the regulation of tissue homeostasis. Innate immune cells are generally affected by CFTR mutations in patients with CF, leading to dysregulation of several cellular signalling pathways that are in continuous use by these cells to elicit a proper immune response. There is substantial evidence to show that airway epithelial cells, neutrophils, monocytes and macrophages all contribute to the pathogenesis of CF, underlying the importance of the CFTR in innate immune responses. The goal of this review is to put into context the important role of the CFTR in different innate immune cells and how CFTR dysfunction contributes to the pathogenesis of CF, highlighting several signalling pathways that may be dysregulated in cells with CFTR mutations.


  • Open Access

    Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis

    by Heledd H Jarosz-Griffiths, Thomas Scambler, Chi H Wong, Samuel Lara-Reyna, Jonathan Holbrook, Fabio Martinon, Sinisa Savic, Paul Whitaker, Christine Etherington, Giulia Spoletini, et al.

    Previously, we showed that serum and monocytes from patients with CF exhibit an enhanced NLRP3-inflammasome signature with increased IL-18, IL-1β, caspase-1 activity and ASC speck release (Scambler et al. eLife 2019). Here we show that CFTR modulators down regulate this exaggerated proinflammatory response following LPS/ATP stimulation. In vitro application of ivacaftor/lumacaftor or ivacaftor/tezacaftor to CF monocytes showed a significant reduction in IL-18, whereas IL-1β was only reduced with ivacaftor/tezacaftor. Thirteen adults starting ivacaftor/lumacaftor and eight starting ivacaftor/tezacaftor were assessed over three months. Serum IL-18 and TNF decreased significantly with treatments, but IL-1β only declined following ivacaftor/tezacaftor. In (LPS/ATP-stimulated) PBMCs, IL-18/TNF/caspase-1 were all significantly decreased and IL-10 was increased with both combinations. Ivacaftor/tezacaftor alone showed a significant reduction in IL-1β and pro-IL-1β mRNA. This study demonstrates that these CFTR modulator combinations have potent anti-inflammatory properties, in addition to their ability to stimulate CFTR function, which could contribute to improved clinical outcomes.


  • Open Access

    ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis

    by Thomas Scambler, Heledd H Jarosz-Griffiths, Samuel Lara-Reyna, Shelly Pathak, Chi Wong, Jonathan Holbrook, Fabio Martinon, Sinisa Savic, Daniel Peckham, Michael F McDermott

    Cystic Fibrosis (CF) is a monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, resulting in defective CFTR-mediated chloride and bicarbonate transport, with dysregulation of epithelial sodium channels (ENaC). These changes alter fluid and electrolyte homeostasis and result in an exaggerated proinflammatory response driven, in part, by infection. We tested the hypothesis that NLRP3 inflammasome activation and ENaC upregulation drives exaggerated innate-immune responses in this multisystem disease. We identify an enhanced proinflammatory signature, as evidenced by increased levels of IL-18, IL-1β, caspase-1 activity and ASC-speck release in monocytes, epithelia and serum with CF-associated mutations; these differences were reversed by pretreatment with NLRP3 inflammasome inhibitors and notably, inhibition of amiloride-sensitive sodium (Na+) channels. Overexpression of β-ENaC, in the absence of CFTR dysfunction, increased NLRP3-mediated inflammation, indicating that dysregulated, ENaC-dependent signalling may drive exaggerated inflammatory responses in CF. These data support a role for sodium in modulating NLRP3 inflammasome activation.


  • Open Access

    Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1α Arm of the Unfolded Protein Response Results in Exacerbated Inflammation

    by Samuel Lara-Reyna, Thomas Scambler, Jonathan Holbrook, Chi Wong, Heledd H. Jarosz-Griffiths, Fabio Martinon, Sinisa Savic, Daniel Peckham, Michael F. McDermott

    Cystic Fibrosis (CF) is a recessive genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR mutations cause dysregulation of channel function with intracellular accumulation of misfolded proteins and endoplasmic reticulum (ER) stress, with activation of the IRE1α-XBP1 pathway that regulates a subset of unfolded protein response (UPR) genes. This pathway regulates a group of genes that control proinflammatory and metabolic responses in different immune cells; however, the metabolic state of immune cells and the role of this pathway in CF remain elusive. Our results indicate that only innate immune cells from CF patients present increased levels of ER stress, mainly affecting neutrophils, monocytes, and macrophages. An overactive IRE1α-XBP1 pathway reprograms CF M1 macrophages toward an increased metabolic state, with increased glycolytic rates and mitochondrial function, associated with exaggerated production of TNF and IL-6. This hyper-metabolic state, seen in CF macrophages, is reversed by inhibiting the RNase domain of IRE1α, thereby decreasing the increased glycolic rates, mitochondrial function and inflammation. Altogether, our results indicate that innate immune cells from CF patients are primarily affected by ER stress. Moreover, the IRE1α-XBP1 pathway of the UPR is responsible for the hyper-metabolic state seen in CF macrophages, which is associated with the exaggerated inflammatory response. Modulating ER stress, metabolism and inflammation, by targeting IRE1α, may improve the metabolic fitness of macrophages, and other immune cells in CF and other immune-related disorders.


  • TNF receptor signalling in autoinflammatory diseases

    by Heledd H Jarosz-Griffiths, Jonathan Holbrook, Samuel Lara-Reyna, Michael F McDermott

    Autoinflammatory syndromes are a group of disorders characterized by recurring episodes of inflammation as a result of specific defects in the innate immune system. Patients with autoinflammatory disease present with recurrent outbreaks of chronic systemic inflammation that are mediated by innate immune cells, for the most part. A number of these diseases arise from defects in the tumour necrosis factor receptor (TNFR) signalling pathway leading to elevated levels of inflammatory cytokines. Elucidation of the molecular mechanisms of these recently defined autoinflammatory diseases has led to a greater understanding of the mechanisms of action of key molecules involved in TNFR signalling, particularly those involved in ubiquitination, as found in haploinsufficiency of A20 (HA20), otulipenia/OTULIN-related autoinflammatory syndrome (ORAS) and linear ubiquitin chain assembly complex (LUBAC) deficiency. In this review, we also address other TNFR signalling disorders such as TNFR-associated periodic syndrome (TRAPS), RELA haploinsufficiency, RIPK1-associated immunodeficiency and autoinflammation, X-linked ectodermal dysplasia and immunodeficiency (X-EDA-ID) and we review the most recent advances surrounding these diseases and therapeutic approaches currently used to target these diseases. Finally, we explore therapeutic advances in TNF-related immune-based therapies and explore new approaches to target disease-specific modulation of autoinflammatory diseases.


  • Top Cited Papers
    Open Access

    Tumour necrosis factor signalling in health and disease

    by Jonathan Holbrook, Samuel Lara-Reyna, Heledd Jarosz-Griffiths, Michael F. McDermott

    The master pro-inflammatory cytokine, tumour necrosis factor (TNF), has been shown to modulate multiple signalling pathways, with wide-ranging downstream effects. TNF plays a vital role in the typical immune response through the regulation of a number of pathways encompassing an immediate inflammatory reaction with significant innate immune involvement as well as cellular activation with subsequent proliferation and programmed cell death or necrosis. As might be expected with such a broad spectrum of cellular effects and complex signalling pathways, TNF has also been implicated in a number of disease states, such as rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease. Since the time of its discovery over 40 years ago, TNF ligand and its receptors, TNF receptor (TNFR) 1 and 2, have been categorised into two complementary superfamilies, namely TNF (TNFSF) and TNFR (TNFRSF), and 19 ligands and 29 receptors have been identified to date. There have been significant advances in our understanding of TNF signalling pathways in the last decade, and this short review aims to elucidate some of the most recent advances involving TNF signalling in health and disease.


  • Regulation of the Unfolded Protein Response in Disease: Cellular Stress and microRNAs

    by Samuel Lara-Reyna, Thomas Scambler, Jonathan Holbrook, Heledd H. Jarosz-Griffiths, Daniel Peckham, Michael F. McDermott

    Abstract: Background: The Unfolded Protein Response (UPR) is a well conserved mechanism that mammalian cells use to cope with stress and infections. This mechanism is exquisitely regulated at several levels, including post-transcriptional modifications by microRNAs. These small non-coding RNAs are mainly involved in the degradation of mRNA, thereby blocking protein translation. The finely balanced interplay between the UPR and microRNAs is altered in several disorders, contributing to both disease aetiology and pathology. Methods: We review and explore alterations in the UPR and microRNAs in several inflammatory conditions, including bone, lung, and neurodegenerative diseases. We also evaluate the impact of these alterations on the disruption of cellular homeostasis and suggest possible therapeutic options to restore this balance. Results: Several components of the UPR, including IRE1, ATF6, and PERK, are clearly dysregulated in inflammatory bone, lung, and neurodegenerative diseases, contributing to the inflammatory process in these disorders. XBP1s, which is downstream of IRE1, is shown to be dysregulated in several diseases, and significantly contributes to the inflammatory process. MicroRNAs show unique dysregulated signatures in each individual tissue and disorder, suggesting that these small transcripts may regulate different pathways in a cell-dependent manner. Finally, there are functional connections between these dysregulated microRNAs and the UPR, which may underlie important pathological aspects of these disorders. Conclusion: It is evident that microRNAs regulate several components of the UPR and that these small non-coding RNAs, or other molecules that restore the UPR balance, may represent possible therapeutic options to normalise intracellular homeostasis.